From: Contrast-enhanced spectral mammography: successful initial clinical institute experience
Variable |  | Final diagnosis | χ2(df,1) | p-value | |||
---|---|---|---|---|---|---|---|
Benign (n = 37) | Malignant (n = 86) | ||||||
n | % | n | % | ||||
Number of lesions by SMG | Nil | 6 | 16.2% | 0 | 0.0% | 14.506 | < 0.001* |
Single lesion | 31 | 83.8% | 65 | 75.6% | |||
2 lesions | 0 | 0.0% | 12 | 14.0% | |||
3 lesions | 0 | 0.0% | 5 | 5.8% | |||
4 lesions | 0 | 0.0% | 4 | 4.7% | |||
BIRADS class by SMG | BIRADS 1 | 4 | 10.8% | 3 | 3.5% | 31.321 | < 0.001* |
BIRADS 2 | 0 | 0.0% | 0 | 0.0% | |||
BIRADS 3 | 15 | 40.5% | 8 | 9.3% | |||
BIRADS 4 | 16 | 43.2% | 24 | 27.9% | |||
BIRADS 5 | 1 | 2.7% | 3 | 3.5% | |||
BIRADS 6 | 1 | 2.7% | 48 | 55.8% | |||
Number of enhanced lesions by CESM | Nil | 14 | 37.8% | 8 | 9.3% | 22.991 | < 0.001* |
Single lesion | 22 | 59.5% | 39 | 45.3% | |||
2 lesions | 0 | 0.0% | 12 | 14.0% | |||
3 lesions | 1 | 2.7% | 21 | 24.4% | |||
4 lesions | 0 | 0.0% | 5 | 5.8% | |||
5 lesions | 0 | 0.0% | 1 | 1.2% | |||
Grade of enhancement | No enhancement | 16 | 43.2% | 8 | 9.3% | 25.294 | < 0.001* |
Minimal | 0 | 0.0% | 12 | 14.0% | |||
Mild | 10 | 27.0% | 1 | 1.2% | |||
Moderate | 8 | 21.6% | 6 | 7.0% | |||
Marked | 3 | 8.1% | 59 | 68.6% | |||
BIRADS class by CESM | BIRADS 1 | 0 | 0.0% | 0 | 0.0% | 71.990 | < 0.001* |
BIRADS 2 | 28 | 75.7% | 1 | 1.2% | |||
BIRADS 3 | 1 | 2.7% | 1 | 1.2% | |||
BIRADS 4 | 7 | 18.9% | 30 | 34.9% | |||
BIRADS 5 | 0 | 0.0% | 8 | 9.3% | |||
BIRADS 6 | 1 | 2.7% | 46 | 53.5% | |||
BIRADS class by SMG | Probably benign (BIRADS 1–3) | 19 | 51.4% | 11 | 12.8% | 20.859 | < 0.001§ |
Probably malignant BIRADS 4–6 | 18 | 48.6% | 75 | 87.2% | |||
BIRADS class by CESM | Probably benign (BIRADS 1–3) | 29 | 78.4% | 2 | 2.3% | 79.375 | < 0.001§ |
Probably malignant BIRADS 4–6 | 8 | 21.6% | 84 | 97.7% | |||
Marked enhancement | No to moderate enhancement | 34 | 91.9% | 27 | 31.4% | 37.874 | < 0.001§ |
Marked enhancement | 3 | 8.1% | 59 | 68.6% |